Since the previous M.D. Anderson Solid Tumor Oncology Series publication on pancreatic cancer, there have been major advances in our understanding of molecular events which underlie pancreatic cancer development, both in the sporadic and inherited forms. We have seen the development of the first mouse models that accurately recapitulate features of the human disease. Several landmark clinical trials in both resectable and metastatic pancreatic cancer have been completed, raising new questions about the standard of care in this disease. Finally, the era of targeted biologic therapies has engendered new excitement about the prospects of more rapid progress in understanding and successfully treating this dreadful disease. Therefore, it is an appropriate time to review these important advances and outline areas of controversy and question in pancreatic cancer biology and treatment. TOC:Series Preface.- Preface.- Section I: Molecular Pathology and Epidemiology.- Spectrum of human pancreatic neoplasia.- Molecular genetics of human pancreatic cancer.- Pancreatic intraepithelial neoplasia: Intraductal papillary mucinous neoplasia.- Familial Pancreatic Familial Chronic Pancreatitis and Pancreatic Cancer Risk.- Section II: Pancreatic Cancer Biology.- Pancreatic stem cells: injury and regeneration.- Pancreatic developmental biology.- Experimental systems for pancreatic cancer research.- Kras-based mouse models.- Cell signaling pathways in pancreatic cancer.- Pancreatic cancer genomics and proteomics.- Section III: Pancreatic Cancer Staging.- Radiologic Staging.- The Role of PET scanning in Pancreatic Cancer.- Endoscopic Ultrasound Staging.- Laparoscopic Staging.- Section IV: Surgery for Pancreatic Cancer.- Pancreaticoduodenectomy: Past to Present.- Total Pancreatectomy.- Distal Pancreatectomy.- Vascular Resection for Pancreatic Cancer.- Management of Postoperative Complications following pancreaticoduodenectomy.- Controversies in surgical management of pancreatic cancer.- Regionalization.- Laparoscopic Resection.- Surgical management of IPMN.- Section V: Palliation of Pancreatic Cancer.- Cancer Pain and symptom management- drug therapy.- Supportive Care: cachexia, anorexia syndrome.- Endoscopic Palliation.- Section VI: Multimodality Therapy of Pancreatic Cancer.- State of the art in radiation therapy for pancreas cancer.- Role of radiosensitizers in the therapy of pancreas cancer.- Optimum cytotoxic therapy for advanced pancreas cancer.- Recent advances in adjuvant therapy for pancreas cancer.- Neoadjuvant therapy for resectable pancreas cancer.- Role of the pathologist in optimizing therapy for pancreas cancer.- Section VI. Emerging Targeted Therapies.- An overview of the molecular targets for new drug development.- The convergence of therapeutic and preventive strategies for pancreas cancer.- Utility of animal models in drug development.- Targeting the K-Ras oncogene.- HER family of receptors as treatment targets.- GSK3B and protein kinase C as potential targets.- Anti-angiogenesis strategies.- Strategies to reduce the activation of NFkB.- Combined approaches to targeted therapies.- Development of vaccine therapy for pancreas cancer.- Modulation of radiation therapy with targeted agents.- Incorporation of genomics and proteomics in drug development.- Pitfalls in the design of clinical trials and future directions.- Index.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.